Qed Therapeutics, A Bridgebio Company

This study tested an oral medication called infigratinib in 84 children aged 3 to 11 with achondroplasia, the most common form of dwarfism. The drug aims to improve growth by targeting a specific protein linked to the condition. Researchers measured safety, side effects, and how …

This study tested a drug called infigratinib in 114 children aged 3 to 18 with achondroplasia, the most common form of dwarfism. The goal was to see if it could safely increase their growth rate over one year compared to a placebo. Participants had already been in an earlier obse…

This study followed 271 children with achondroplasia (ages 2.5 to 17) to understand their growth, medical issues, and quality of life over time. No medication was given. The goal was to gather natural history data to help design future treatments.